Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-25-072172·BridgeBio Oncology Therapeutics, Inc.
Schedule 13G ownership disclosure
HELIX ACQUISITION CORP II
Class A Ordinary Shares, par value $0.0001 per share · CUSIP: G4444H101
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Integrated Core Strategies (US) LLC
Shares: 833,125.00 · Class: 4.4%
- Millennium Management LLC
Shares: 897,251.00 · Class: 4.7%
- Millennium Group Management LLC
Shares: 897,251.00 · Class: 4.7%
- Israel A. Englander
Shares: 897,251.00 · Class: 4.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-072172
- Form type
- SCHEDULE 13G/A
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Jul 30, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership